Listed

Emergent BioSolutions Inc.: Form 10-Q for the period ended Jun 30, 2016

Filed with the SEC on Aug 5, 2016 and accepted by EDGAR at Aug 5, 2016, 16:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-04-01 to 2016-06-30$101.5mus-gaap:SalesRevenueNet
Revenue6 months2016-01-01 to 2016-06-30$212.5mus-gaap:SalesRevenueNet
Cost of revenue3 months2016-04-01 to 2016-06-30$35.6mus-gaap:CostOfGoodsSold
Cost of revenue6 months2016-01-01 to 2016-06-30$64.1mus-gaap:CostOfGoodsSold
Research and development3 months2016-04-01 to 2016-06-30$35.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-01-01 to 2016-06-30$69.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2016-04-01 to 2016-06-30$44.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2016-01-01 to 2016-06-30$83.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-04-01 to 2016-06-30−$13.6mus-gaap:OperatingIncomeLoss
Operating income6 months2016-01-01 to 2016-06-30−$5.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-04-01 to 2016-06-30$1.5mus-gaap:InterestExpense
Interest expense6 months2016-01-01 to 2016-06-30$3.0mus-gaap:InterestExpense
Income tax3 months2016-04-01 to 2016-06-30−$3.9mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2016-01-01 to 2016-06-30−$597.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-04-01 to 2016-06-30−$10.9mus-gaap:NetIncomeLoss
Net income6 months2016-01-01 to 2016-06-30−$7.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-04-01 to 2016-06-30−$0.27us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2016-01-01 to 2016-06-30−$0.17us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-04-01 to 2016-06-30−$0.27us-gaap:EarningsPerShareBasic
Basic EPS6 months2016-01-01 to 2016-06-30−$0.17us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-04-01 to 2016-06-3040,202,821 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2016-01-01 to 2016-06-3039,872,738 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Capital expenditure6 months2016-01-01 to 2016-06-30$39.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-06-30$333.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$528.0mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$1.06bnus-gaap:Assets
Current liabilitiesAt period end2016-06-30$103.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$383.8mus-gaap:Liabilities
Long-term debtAt period end2016-06-30$247.4mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2016-06-30$672.7mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001367644-16-000074. Last ingested by Listed: Nov 4, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.